Media stories about Beigene (NASDAQ:BGNE) have trended somewhat positive on Monday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Beigene earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.7217403422699 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
Several analysts recently issued reports on BGNE shares. Maxim Group set a $120.00 price target on Beigene and gave the stock a “buy” rating in a report on Monday, December 11th. Cowen reissued a “buy” rating on shares of Beigene in a report on Monday, December 11th. ValuEngine downgraded Beigene from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. BidaskClub raised Beigene from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Finally, Zacks Investment Research downgraded Beigene from a “hold” rating to a “sell” rating in a report on Monday, January 8th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $127.67.
Beigene stock traded up $5.46 on Monday, reaching $163.61. The company had a trading volume of 638,417 shares, compared to its average volume of 380,979. Beigene has a 12-month low of $34.36 and a 12-month high of $166.00. The company has a current ratio of 6.09, a quick ratio of 6.02 and a debt-to-equity ratio of 0.23. The firm has a market cap of $8,471.30, a PE ratio of -67.05 and a beta of 0.58.
Beigene (NASDAQ:BGNE) last posted its earnings results on Wednesday, February 28th. The company reported ($2.19) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.40). The company had revenue of $18.17 million during the quarter, compared to analysts’ expectations of $23.00 million. equities analysts predict that Beigene will post -7.69 EPS for the current fiscal year.
In related news, EVP Ji Li sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $146.88, for a total value of $1,468,800.00. Following the sale, the executive vice president now directly owns 10,000 shares in the company, valued at approximately $1,468,800. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO John Oyler sold 20,137 shares of the firm’s stock in a transaction that occurred on Tuesday, December 26th. The shares were sold at an average price of $96.46, for a total value of $1,942,415.02. Following the completion of the sale, the chief executive officer now owns 110,179 shares in the company, valued at $10,627,866.34. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 164,475 shares of company stock worth $22,963,626. 19.90% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/19/beigene-bgne-earning-somewhat-positive-media-coverage-study-finds.html.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.